SOURCE: Erchonia

Erchonia | Laser Healthcare

April 20, 2010 13:29 ET

Erchonia Presents New Laser Studies at 2010 ASLMS Conference

Pilot Studies Explore Low Level Laser's Effect on LDL, Leptin and Parkinson's Disease

MCKINNEY, TX--(Marketwire - April 20, 2010) -  Erchonia, the global leader in low level laser healthcare applications, presents three new studies at the upcoming American Society for Laser Medicine and Surgery Annual Conference this week in Phoenix, Arizona.

Erchonia will be presenting a study it conducted using low level lasers to treat late stage Parkinson's disease. Eight volunteers between 18 and 80 years with late stage PD participated in the non-controlled, non-randomized study and received low level laser treatments daily for two weeks. Patients were asked to rate the severity of their symptoms (balance, gait, freezing, cognitive function, rolling in bed, and speech difficulties) from 0 to 10 using the Visual Analog Scale. All participants demonstrated a decrease in VAS from baseline to study endpoint.

The second study Erchonia plans to present shows how low level lasers may reduce low-density lipoprotein levels (LDL). Forty-one patients between 18 and 65 years participated in the non-controlled, non-randomized study. Partipants received a 40-minute ZERONA laser treatment three times a week for two weeks and demonstrated a reduction in low-density lipoprotein levels of 12.05 points, a 13% reduction. This study suggests that low level laser therapy may serve as a non-invasive way to reduce LDL levels in two weeks.

Erchonia's third study explores how its ZERONA laser impacts leptin levels, the hormone linked to hunger. Twenty volunteers between the ages of 18 and 65 participated in Erchonia's non-controlled, non-randomized study. Participants received 40-minute ZERONA low level laser treatments, three times per week for two weeks. All participants demonstrated a reduction in leptin levels compared to their baseline -- on average, a 50% decrease. Since leptin levels are associated with hunger, this study shows how low level laser technology may non-invasively suppress the appetite.

Ryan Maloney, Erchonia's medical director and one of the authors of the studies, comments, "Although these were non-controlled, non-randomized pilot studies, they each showed promising new applications for low level laser technology. Further study is needed, but Erchonia is paving the way for new non-invasive healthcare technologies with a commitment to research and innovation."

For more information, please visit www.erchonia.com.

About Erchonia
Erchonia is the global leader in low level laser healthcare applications. Over the last 15 years, Erchonia has been conducting research & development with the world's leading physicians to advance the science of low level lasers.